BioCentury
ARTICLE | Clinical News

HSV-2 vaccine: Phase II started

April 27, 2015 7:00 AM UTC

Admedus began a double-blind, placebo-controlled, Australian Phase II trial to evaluate 1,000 ug intradermal HSV-2 vaccine every 4 weeks for 12 weeks followed by a 1,000 ug booster injection at 6 mont...